Assessment of 35972 RP (oltipraz) a new antischistosomal drug against Schistosoma haematobium, Schistosoma mansoni, and Schistosoma intercalatum
Gentilini, M.; Duflo, B.; Richard-Lenoble, D.; Brücker, G.; Danis, M.; Niel, G.; Meunier, Y.
Acta Tropica 37(3): 271-274
ISSN/ISBN: 0001-706X PMID: 6106367 Accession: 000825432
Oltipraz (35972 RP) was given to 116 patients infected with Schistosoma haematobium in Mali, to 72 with S. intercalatum in Gabon and to 47 with S. mansoni and 86 with S. haematobium in Paris, France. Judging by faecal or urine egg counts, all cases of S. mansoni were cured by a total dose of 3 to 5 g over 2 to 5 days, and 87% of the cases of S. intercalatum were cured by a total dose of 1.25 to 4.50 g over 3 days. Of the 116 patients with S. haematobium in Mali, 63 received 15 mg/kg body-weight/day for 2 days and 53 received 25 mg/kg/day for 2 days: the cure rates were 86% and 94% respectively. In Paris, 92% of the 86 patients with S. haematobium were cured by a total dose of 2.0 to 7.5 g over one to 5 days.